Physician profile
David Gillespie
NPI 1952336406
$558.83
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.39 · 2020: $81.39 · 2021: $317 · 2022: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.28 | 2019-2021 | |
| Aspira Women'S Health INC | $112.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $81.68 | 2020-2022 | |
| Exeltis, USA INC. | $54.56 | 2021 | |
| Organon LLC | $44.93 | 2021-2022 | |
| Evofem Biosciences, INC. | $31.39 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $22.92 | 2021 | |
| Agile Therapeutics, INC. | $22.32 | 2022 | |
| Hologic Sales and Service, LLC | $16.25 | 2020 | |
| Merck Sharp & Dohme LLC | $15.64 | 2021 | |
| Therapeuticsmd, INC. | $15.52 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.81 | 2020 | |
| Convatec INC. | $11.87 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.